SkinBioTherapeutics PLC Update regarding Nominated Adviser and Broker (2069U)
22 November 2023 - 6:00PM
UK Regulatory
TIDMSBTX
RNS Number : 2069U
SkinBioTherapeutics PLC
22 November 2023
22 November 2023
SkinBioTherapeutics plc
("SkinBioTherapeutics" or "the Company")
Update regarding Nominated Adviser and Broker
SkinBioTherapeutics plc, (AIM: SBTX, or the "Company"), the life
science business focused on skin health, announces that, following
the completion of the all-share merger between Cavendish Securities
plc (previously named Cenkos Securities plc) and Cavendish
Financial plc (previously named finnCap Group plc), and as a
consequence of internal reorganisation within the Cavendish Group,
the Company has changed its Nominated Adviser and Broker from
Cavendish Securities plc to Cavendish Capital Markets Limited.
For more information please contact:
SkinBioTherapeutics plc Tel: +44 (0) 191 495
Stuart J. Ashman, CEO 7325
Manprit Randhawa, CFO
Cavendish Capital Markets Limited Tel: +44 (0) 20 7220
(Nominated Adviser & Broker) 0500
Giles Balleny, Dan Hodkinson (Corporate
Finance)
Charlie Combe (Broking)
Dale Bellis, Tamar Cranford-Smith (Sales)
Instinctif Partners (financial press) Tel: +44 (0) 20 7457
Melanie Toyne-Sewell / Adam Loudon / 2020
Jack Kincade SkinBioT herapeutics@instinctif.com
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin
health. The Company's proprietary platform technology,
SkinBiotix(R), is based upon discoveries made by Professor
Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors,
the most advanced of which are cosmetic skincare and food
supplements to modulate the immune system by harnessing the
gut-skin axis. In each area SkinBioTherapeutics plans to exemplify
its technology through human studies. The Company's first product,
AxisBiotix-Ps(TM), a food supplement to address the symptoms of
mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in
Newcastle, UK. For more information, visit:
www.skinbiotherapeutics.com and www.axisbiotix.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
APPFFFELLILLFIV
(END) Dow Jones Newswires
November 22, 2023 02:00 ET (07:00 GMT)
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From Apr 2024 to May 2024
Skinbiotherapeutics (LSE:SBTX)
Historical Stock Chart
From May 2023 to May 2024